Supernus Pharmaceuticals, Inc. $SUPN Shares Bought by Royce & Associates LP

Royce & Associates LP grew its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 385.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 197,737 shares of the specialty pharmaceutical company’s stock after purchasing an additional 156,972 shares during the quarter. Royce & Associates LP owned approximately 0.34% of Supernus Pharmaceuticals worth $9,828,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Hantz Financial Services Inc. boosted its stake in Supernus Pharmaceuticals by 81.7% during the 3rd quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock worth $30,000 after purchasing an additional 281 shares during the last quarter. Torren Management LLC acquired a new stake in Supernus Pharmaceuticals during the 4th quarter worth $49,000. Smartleaf Asset Management LLC boosted its stake in Supernus Pharmaceuticals by 30.8% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock worth $54,000 after purchasing an additional 268 shares during the last quarter. Global Retirement Partners LLC boosted its stake in Supernus Pharmaceuticals by 532.4% during the 4th quarter. Global Retirement Partners LLC now owns 1,404 shares of the specialty pharmaceutical company’s stock worth $70,000 after purchasing an additional 1,182 shares during the last quarter. Finally, Vestcor Inc acquired a new stake in Supernus Pharmaceuticals during the 3rd quarter worth $67,000.

Supernus Pharmaceuticals Price Performance

NASDAQ SUPN opened at $46.64 on Thursday. The firm’s 50-day moving average is $49.84 and its two-hundred day moving average is $49.58. Supernus Pharmaceuticals, Inc. has a 12 month low of $30.83 and a 12 month high of $59.68. The stock has a market capitalization of $2.71 billion, a P/E ratio of -91.45, a PEG ratio of 1.03 and a beta of 0.57.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Wall Street Zen cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 23rd. Craig Hallum set a $65.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 25th. Zacks Research raised shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Friday, March 27th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $62.17.

Insider Activity at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, Director Georges Gemayel sold 10,000 shares of the business’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $53.71, for a total transaction of $537,100.00. Following the sale, the director directly owned 28,159 shares in the company, valued at $1,512,419.89. This represents a 26.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Frederick M. Hudson sold 5,369 shares of the business’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $50.61, for a total transaction of $271,725.09. Following the sale, the director owned 60,413 shares in the company, valued at $3,057,501.93. This trade represents a 8.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 116,406 shares of company stock worth $5,911,086. 8.80% of the stock is owned by corporate insiders.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.